GlassScriptPhysician profile
Harish Iyer
NPI 1033325477
$4,542.09
in general payments reported to CMS, 2019-2025
20 companies · $434 in 2025
The $434 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $387 · 2021: $38.52 · 2022: $270 · 2023: $374 · 2024: $2,479 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $1,195 · Education: $92.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $1,195.41 |
| Education | $92.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $2,064.42 | 2024 | Capsocam Colon, Capsocam Plus |
| Abbvie INC. | $811.01 | 2021-2025 | |
| Boston Scientific Corporation | $535.31 | 2019-2020 | |
| Covidien LP | $158.77 | 2019 | |
| Novo Nordisk INC | $139.52 | 2023 | Wegovy |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Gilead Sciences, INC. | $110.91 | 2019 | |
| Ardelyx, INC. | $103.34 | 2023-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $92.10 | 2025 | Givlaari |
| Exact Sciences Corporation | $85.87 | 2024 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $51.31 | 2021-2022 | |
| Pfizer INC. | $47.90 | 2024 | |
| Celgene Corporation | $45.67 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $39.56 | 2024 | Rezdiffra |
| Merck Sharp & Dohme LLC | $32.90 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $28.14 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2024 | Entyvio |
| Ferring Pharmaceuticals INC. | $15.40 | 2025 | Rebyota |
| Intra-Sana Laboratories | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.